The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Yelp Consumer Complaints
Yelp Consumer Complaints
Yelp Consumer Complaints
20261205: EFR Group Holdings S.a.r.l.; Charles Mcllvaine
20261209: General Atlantic Partners 100, L.P.; Farther Finance, Inc.
20261227: Intel Corporation; SambaNova Systems, Inc.
20261229: Uber Technologies, Inc.; Blacklane GmbH
20261247: Lone Star Fund XII, L.P.; Lonza Group AG
20261248: Stryker Corporation; Amplitude Vascular Systems, Inc.
20261250: Credit Union 1; MAC Federal Credit Union
20261252: Nathan P. McCauley; Anchor Labs, Inc.
20261253: Novartis AG; Red Tree Venture Fund, L.P.
20261254: Ferguson Enterprises Inc.; The Peninsula Fund VII Limited Partnership
20261260: Hull Street Energy Partners III, L.P.; Rockland GridFlex Partners, LP
20261261: LGS SJ Evergreen Holdings, LLC; NHRP LOGOS LP
20261277: Giancarlo Devasini; Gold.com, Inc.
20261282: Containment Investment Holdings, LLC; Tower Compactor Rentals, LLC
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.